Business Model Breakdown
How Niagen Bioscience Inc Makes Money
NAGE
Market Cap
$279M
Annual Revenue
$116M
Profit Margin
14.3%
Employees
104
The Short Version
Niagen Bioscience Inc develops and commercializes products centered around nicotinamide riboside (Niagen), a proprietary form of vitamin B3 that supports NAD+ levels in the body, associated with cellular energy and healthy aging. The company earns revenue primarily through the sale of Niagen-containing dietary supplements, often through its own brand or by licensing the ingredient to other consumer product companies. Its business model relies on scientific research to validate the benefits of Niagen, intellectual property protection, and distribution channels to reach consumers in the health and wellness market.
Where the Revenue Comes From
Sale of Niagen-containing dietary supplements and ingredients (approx. 100% of revenue based on focus)
Who buys: Individual consumers (direct-to-consumer and retail), potentially other health and wellness product companies (via ingredient licensing).
Why It Works (Competitive Advantages)
- ✔Proprietary ingredient (Niagen / nicotinamide riboside) with scientific backing.
- ✔Established research program focused on NAD+ precursors.
Economic Moat: Narrow (Intangible Assets/IP (related to Niagen patents and clinical data), Brand Power (if Niagen becomes a recognized ingredient brand))
What Our Analysis Says
DVR Score as of June 10, 2026
Niagen Bioscience Inc (NAGE) is now verifiable as an active public company, a material change from the previous analysis. Its Q1 2026 revenue of $31.5M (up 5% YoY) and analyst coverage with an $11 price target (vs. current $3.51) signal some investment potential. However, current growth is modest for 10x aspirations, and detailed financial health (profitability, cash flow) is not provided in the brief, likely implying an early-stage or cash-burning profile common in the biotech/supplement sector. The market opportunity in longevity is significant, but competitive advantages need stronger validation. Despite the analyst's 'Buy' rating, the price target reduction suggests some caution. Overall, it's an investable company, but significant risks remain, and strong catalysts for exponential growth are not yet evident.